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Conclusion: Despite the numerous publications on focal 
therapy in prostate cancer, primary FRT is largely 
unexplored. Radiotherapy appears to be particularly suitable 
as a focal approach, since it has an established biological 
basis, known tumoricidal activity, possibility of dose 
differentiation, large availability of high-precision dose 
delivery techniques, limited or no invasiveness and 
familiarity to radiation oncologists and urologists. However, 
when applied as primary FRT, its use remains investigational 
since numerous questions remain unmet: consensus on the 
initial diagnostic tools, the optimization of technical 
parameters for therapy delivery, follow-up exams and 
scheduling, tumour control and toxicity profile, response 
evaluation and failure definition, salvage therapy and cost-
benefit.  
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Purpose or Objective: Changes in prostate and tumour ADC 
values during radiotherapy (RT) may aid prediction of 
response to treatment. Intermediate and high risk patients 
are likely to receive neoadjuvant hormone therapy (NA-HT) 
prior to RT, causing reduction in prostate and tumour volume 
and changes in ADC values. It is unclear how this affects 
further ADC changes during subsequent treatment. We 
assessed ADC values in prostate tumour and normal tissue 
during RT after NA-HT. 
 
Material and Methods: Fifteen patients with ≥T2b disease 
who were due to receive RT (60 Gy in 20 fractions) were 
recruited after 3 months of NA-HT. Patients underwent three 
1.5 T MRI examinations: post NA-HT (one week prior to RT), 
at the end of the third week of treatment, and eight weeks 
after RT completion. The imaging protocol included T2 
weighted and diffusion weighted imaging, acquired using the 
cardiac coil (EPI with TR/TE 8000/70 ms, b = 100, 400, 800 
s/mm²). ADC maps were processed offline (ADCmap for 
Osirix). Normal central gland (CG), peripheral zone (PZ) and 
tumour were outlined on T2w images by a radiologist expert 
in prostate MRI, with pre-NA-HT imaging (T2w and DWI) 
available in 12 patients to aid identification. If disease was 
not clearly visible, clinical findings and biopsy results were 
used to aid delineation. CG, PZ and tumour regions were 
transferred to the ADC maps and median values extracted 
along with interquartile ranges. A Mann-Whitney U test was 
used to analyse differences between tumour and normal 
tissue regions at the three time points. 
 
Results: 13 patients completed all scans, 2 patients missed 1 
and 2 scans respectively. After NA-HT, there was a significant 
difference between median tumour and PZ (p=0.009) and 
tumour and CG (p=0.002) (median values plotted in figure 1). 
At the other time points, there was no difference between 
tumour and normal tissue ADCs. 
 
 
 
Conclusion: The ADC values display a similar pattern to that 
seen in previous studies for patients receiving RT alone. The 
difference between tumour and normal tissue was smaller at 
baseline than has been seen in other work without NA-HT. 
This may be due to a reduction in normal tissue ADC during 
induction therapy, whilst tumour ADC values could have 
increased due to tumour shrinkage. Variation in imaging 
protocol for ADC measurement compared to previous studies 
may also play a role. The reduced magnitude of changes in 
tumour ADC seen during RT after NA-HT may make its use as 
a predictive tool for treatment response more challenging in 
this group of patients. 
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Purpose or Objective: At the time of a biochemical 
recurrence after prostatectomy it is important to distinguish 
patients who have a local recurrence from patients with 
distant metastasis. PET/CT and MRI are important imaging 
modalities that can be used in this scenario. The purpose of 
this study was to investigate the outcomes and toxicities of 
patients in a large single-institution cohort treated with 
salvage radiotherapy (sRT) and dose escalation up to 72 Gy. 
Boost planning was based on MRI or PET/CT. 
 
Material and Methods: From 2008 to 2012 290 patients who 
received sRT were included into the analysis. Patients with a 
PSA > 1 ng/ml or a PSA doubling time > 3 months received a 
Choline PET/CT before the start of radiotherapy. 
Additionally, in most patients MRI of the pelvis was 
conducted. If there was a macroscopic tumor recurrence, 
defined as local recurrence in the prostate bed in MRI or PET 
tracer uptake, radiation therapy to the prostatic bed was 
